Results 101 to 110 of about 47,824 (192)

Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi, Stephen Twumasi, Linda K. Olaga, Benedict Sackey, Daniel N. M. Antonio, Richard O. Ansah, Eugene A. Ansah, John A. Sah, Enoch O. Anto, Yvonne Anang‐Quartey, Antoinette Koomson, Angela Opoku, Godfred A. Donkor, Paulina Duah, Ama G. Boadu, Samuel Essien‐Baidoo, Wina I. O. Boadu, Lilian A. Boateng   +17 more
wiley   +1 more source

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang, D. Q. Cai, Zhen Zhao, Zhixiang Jian, Mude Shi, Yajin Chen, Jueming Chen, Chunhua Qu, Diankui Cai   +8 more
wiley   +1 more source

Passenger variants as pan‐clonal markers of pediatric AML: Implications for molecular MRD

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract A streamlined, sensitive, and universal molecular method for MRD detection in pediatric AML remains an unmet clinical need. Here, we propose a novel approach based on tracking somatic non‐coding passenger variants. Using whole‐genome sequencing (WGS) of diagnostic bone marrow DNA, we identify patient‐specific somatic passenger variants, which ...
Ruth Shiloh, Dana Dayan, Ifat Geron, Maor Cohen, Tamar Feuerstein, Jorge Cano‐Nistal, Nurit Gal‐Mark, Shlomit Barzilai‐Birenboim, Dafna Gaash, Michal Hameiri‐Grossman, Avraham Kahan, Jamal Mahajna, Nino Oniashvili, Hava Rosenfeld, Dan Scharf, Keren Shichrur, Elena Shinderman‐Maman, Sarah Elitzur, Yehudit Birger, Shai Izraeli, Yosef E. Maruvka   +20 more
wiley   +1 more source

Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi‐LMC study

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract The rarer p190 (e1a2) transcript in chronic myeloid leukemia (CML) is associated with atypical presentations; yet, its biological basis remains poorly understood. Using a cohort of 60 patients including 42 chronic phase patients age‐matched 1:1 with 42 e13a2/e14a2 patients in the chronic phase, we investigated the clinical, genomic, and clonal
Benjamin Podvin, Olivier Nibourel, Sandrine Hayette, Valérie Coiteux, Rathana Kim, Lucie Rigolot, Stéphanie Dulucq, Augustin Boudry, Geoffrey Pawlak, Wayne‐Corentin Lambert, Pascale Flandrin‐Gresta, Ivan Sloma, Christophe Roumier, Marie Balsat, Sandrine Loron, Chloé Li, Sandrine Geffroy, Jean‐Michel Cayuela, Françoise Huguet, François‐Xavier Mahon, Franck E. Nicolini, Delphine Réa, Claude Preudhomme, Nicolas Duployez, Catherine Roche‐Lestienne, Fi‐LMC group   +25 more
wiley   +1 more source

Salvage With Revumenib: Targeting KMT2A‐Rearranged Isolated Leukemia Cutis Identified in the Extramedullary Disease

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a high risk of relapse. Leukemia cutis is characterized by the presence of neoplastic leukocytes infiltrating the skin. Here, we present a previously treated AML patient who relapsed with isolated leukemia cutis without bone marrow involvement. Fluorescence in
Bana Antonios, Xuemei Wu, Lynn Johnson, Avani Ahuja, Megan Blauvelt, Margaret Aronckes, Nina Dutton, Jennifer Dujmic, Salman Fazal, Taimoor I. Sheikh   +9 more
wiley   +1 more source

Sinusoidal Obstruction Syndrome With Inotuzumab Ozogamicin Combined With Ponatinib for Philadelphia‐Chromosome‐Positive Lymphoblastic Malignancies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Sinusoidal obstruction syndrome, also known as veno‐occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin‐based antibody‐drug conjugate. Case Presentation We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without ...
Emi Yokoyama, Satoshi Ota, Yasuo Sakurai, Toma Suzuki, Naoki Miyashita, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Akio Mori, Takeshi Kondo   +10 more
wiley   +1 more source

SIRT Family: Biological Functions and Therapeutic Targets

MedComm, Volume 7, Issue 8, August 2026.
SIRT1–SIRT7 networks from transgenic mice to human‑relevant therapeutic targets. SIRT1–SIRT7 form an isoform‑, organ‑, and disease‑specific regulatory network. Transgenic Sirt1–7 mouse models define central regulatory SIRTs (SIRT1, SIRT3, SIRT6), context‑dependent modifiers (SIRT2, SIRT4, SIRT5, SIRT7), and their key mechanisms and target organs. These
Jia‐Yi Wang, Feng‐Li Jiang, Fang‐Yuan Zhang, Dong‐Hui Huang, Xiao‐Ying Li, Song Gao, Hua You, Qi‐Jun Wu, Huan‐Huan Chen, Ting‐Ting Gong   +9 more
wiley   +1 more source

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

The Journal of Pathology, Volume 269, Issue 4-5, Page 387-398, August 2026.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov, Juliana Faria Filipe, Sylvia Eidenhammer, German Ott, Iris Halbwedl, Karl Kashofer, Helmut Popper   +6 more
wiley   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source

Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL‐Fusion Leukemia

Cancer Science, Volume 117, Issue 8, Page 2221-2235, August 2026.
Combined SETD2 and menin inhibitors make synergistic effects against MLL‐fusion leukemia; the combination therapy reduces the expression of target genes through blocking transcription elongation and initiation. ABSTRACT During transcriptional elongation, the histone methyltransferase SETD2 binds to RNA polymerase II and deposits trimethylation marks at
Anpei Li, Yuan Zhang, Ziwei Li, Anhao Liu, Li Zhang, Shubin Gao, Xiao Lin, Xiaoming Liu, Huan Li, Guanghui Jin, Bin Xu   +10 more
wiley   +1 more source